How Often Does IVF Work the First Time?

Roughly three in ten IVF cycles result in a live birth on the first attempt. Large population studies place the first-cycle live-birth rate somewhere around 29 to 33 percent, though that number shifts dramatically depending on the woman’s age, the cause of infertility, and the clinic’s approach to embryo transfer. What surprises many people is how much the odds improve when you look beyond that single first try, and how many controllable factors can nudge the number in either direction.

What the Numbers Actually Say

Two of the largest studies on first-cycle IVF outcomes arrive at strikingly similar figures. A UK-based analysis of nearly 114,000 women found that 29.1 percent had a live birth after their first complete cycle.¹ A separate study covering over 156,000 women reported a virtually identical figure of 29.5 percent for all comers, rising to 32.3 percent for women under 40 using their own eggs.² A third institutional study put the number at 33 percent.³

It is worth understanding what “complete cycle” means in these studies. A complete cycle includes the egg retrieval, the fresh embryo transfer, and the transfer of any frozen embryos created from that same retrieval. So one complete cycle can involve more than one transfer attempt. That distinction matters because a single retrieval often produces multiple embryos, giving you more than one shot before starting the stimulation process again.

Age Is the Single Strongest Predictor

No other factor shapes first-cycle outcomes as powerfully as the age of the person providing the eggs. The numbers drop off sharply once a woman crosses 40. In the large UK dataset, women aged 40 to 42 had a first-cycle live-birth rate of about 12 percent, and women older than 42 fell below 4 percent per cycle.² The biological reasons are well understood: egg quality declines with age, driven largely by a rising rate of chromosomal abnormalities in the eggs and reduced mitochondrial function.⁴

This does not mean IVF is pointless after 40. It means that a single cycle is less likely to work, and more cycles are usually needed. For women 40 to 42, six cycles brought the cumulative live-birth rate up to about 31 percent after adjusting for prognosis, a number that roughly catches up to where younger women start on their first try.² For women under 35, the picture is more encouraging: cumulative rates after six cycles reached 65 to 86 percent depending on the estimation method used.⁵

Why Multiple Cycles Matter More Than the First

Focusing too narrowly on first-cycle success rates can be misleading. IVF is often a cumulative process, and the odds climb with each attempt. After three complete cycles, cumulative live-birth rates for women under 40 have been reported at around 51 to 57 percent.⁶ After six cycles, the UK study found a cumulative rate of 43 percent across all ages, while analyses focusing on younger women or using optimistic assumptions (which count people who dropped out as if they would have had average outcomes) have reported figures as high as 72 to 82 percent.⁵⁷

The gap between “optimistic” and “conservative” cumulative estimates is not just a statistical quirk. It reflects the dropout problem: many couples stop IVF before they have exhausted their chances, and we do not know how they would have fared. That is why the conservative and optimistic estimates can differ by 20 or more percentage points for the same population.

The Dropout Problem

A large proportion of people who do not succeed on their first cycle never come back for a second. The physical toll, emotional strain, and financial cost all contribute. A prospective study found that the physical or psychological burden of treatment was the most common reason couples dropped out, accounting for about 28 percent of discontinuations.⁸ In systems where IVF is publicly funded and patients are actively supported, the dropout rate between the first and second cycle can be much lower. A New Zealand program with funded cycles reported only about 10 percent of couples dropping out for stress-related reasons.⁹

This means that the cumulative success rates in the literature almost certainly underestimate what would happen if everyone who started IVF kept going for several cycles. The people who drop out are not randomly distributed: some leave because their prognosis is poor, but many leave simply because they cannot afford another round or are too exhausted to continue. For those who can persist, the math continues to work in their favor with each additional attempt.

Fresh Versus Frozen Embryo Transfers

One of the decisions that shapes first-cycle outcomes is whether to transfer an embryo fresh (days after egg retrieval) or freeze all embryos and transfer one in a later cycle. The evidence on this has shifted over the past decade, and it is not entirely settled. A systematic review and meta-analysis of randomized trials in women roughly aged 27 to 33 found that frozen embryo transfer led to higher ongoing and clinical pregnancy rates, possibly because the uterine lining has more time to recover from the hormonal stimulation used to retrieve eggs.¹⁰ A larger retrospective study similarly found higher live-birth rates with frozen transfers.¹¹

However, one randomized trial comparing a freeze-all strategy to conventional fresh transfer found that the freeze-all group actually had a lower ongoing pregnancy rate, and the difference in live births was not statistically significant.¹² The takeaway is that frozen transfers work well and may offer advantages for certain patients, particularly those at risk of ovarian hyperstimulation, but a blanket freeze-all approach does not guarantee better results for everyone.

How Many Embryos Should Be Transferred

Transferring two embryos instead of one might seem like an easy way to double your odds, but the math is not that simple. A landmark randomized trial found that double embryo transfer produced a live birth in about 43 percent of women compared to about 39 percent with single embryo transfer. The difference was modest. What was not modest was the multiple-birth rate: 33 percent of successful pregnancies in the double-transfer group were twins, compared to under 1 percent in the single-transfer group.¹³

Twin pregnancies carry meaningfully higher risks of preterm birth, low birth weight, and complications for both the mother and babies. A more recent analysis found that elective single embryo transfer actually had a higher live-birth rate than double transfer (about 41 percent versus 33 percent), and that when you added in a second frozen single transfer from the same cycle, the cumulative rate climbed to nearly 48 percent.¹⁴ The trend in most countries with well-regulated fertility care is firmly toward single embryo transfer, especially for younger patients with good-quality embryos.

Underlying Diagnoses Shift the Odds

The reason you need IVF in the first place has a real effect on how well the first cycle works. Couples dealing with severe male factor infertility, for example, often require a specialized technique called intracytoplasmic sperm injection, where a single sperm is injected directly into the egg. An early landmark study found that ICSI achieved a fertilization rate of 76 percent in cases where standard IVF could only manage 15 percent, with a pregnancy rate of 33 percent per transfer.¹⁵ ICSI has essentially solved the fertilization problem for severe male factor cases, though it adds cost and complexity.

Endometriosis presents a different challenge. A systematic review and meta-analysis found that women with endometriosis produced fewer eggs per retrieval and had a lower live-birth rate compared to women without the condition, even though clinical pregnancy rates were similar between the two groups.¹⁶ The gap between clinical pregnancy and live birth rates in these patients suggests a higher rate of early pregnancy loss, which is consistent with the inflammatory nature of endometriosis and its effects on the uterine environment.

Body Weight and IVF Outcomes

Obesity is one of the more modifiable factors that affects first-cycle success. A systematic review found that for every five-unit increase in BMI, the clinical pregnancy rate and live-birth rate dropped by roughly 5 to 7 percent, while miscarriage rates rose by about 9 percent.¹⁷ A study focused specifically on first ART cycles found the effect was even more stark at higher BMIs: women with a BMI of 35 or above had roughly 60 to 68 percent lower odds of a live birth compared to normal-weight women.¹⁸

The relationship between weight and IVF success is not identical across all ages. A study that broke down results by age found that the effect was most pronounced in women aged 30 to 38, where normal-weight women had significantly higher implantation, pregnancy, and live-birth rates compared to overweight and obese women.¹⁹ Being underweight was not harmful in that study and was actually associated with some favorable lab markers, though the clinical significance of that finding is unclear. For patients who have time before starting IVF, weight loss in the overweight-to-obese range is one of the few lifestyle changes with strong evidence of improving first-cycle odds.

Preimplantation Genetic Testing

Preimplantation genetic testing for aneuploidy, known as PGT-A, screens embryos for chromosomal abnormalities before transfer. The idea is straightforward: by selecting only chromosomally normal embryos, you avoid transferring ones destined to fail. A large real-world study found that women using PGT-A had a first-transfer live-birth rate of about 53 percent, compared to 34 percent without testing.²⁰ That sounds like a clear win, but the picture is more complicated than it appears.

The per-transfer rate goes up because you are only transferring pre-screened embryos. But testing itself discards some embryos that might have been viable, and the process adds a cycle of waiting. When researchers looked at good-prognosis patients (those expected to do well with IVF regardless), PGT-A did not improve live-birth rates across any age group. Women under 35 had essentially identical outcomes whether their embryos were tested or not, and the same was true for women 35 to 37 and women over 37.²¹ PGT-A likely benefits patients with recurrent implantation failure or older women with many embryos to choose from, but it is not a universal booster for first-cycle success.

PGT-A should not be confused with PGT-M, which tests for specific inherited genetic conditions like cystic fibrosis or sickle cell disease. Patients undergoing PGT-M are testing for a known family mutation, not screening for chromosomal abnormalities in general. One center reported a live-birth rate per transfer of about 45 percent in PGT-M cycles, though patients who also had underlying fertility problems were nearly half as likely to achieve a pregnancy compared to those who were fertile but carried a genetic condition.²²

Ovarian Reserve Markers and What They Predict

Before starting IVF, most clinics measure ovarian reserve using two main tools: a blood test for anti-Müllerian hormone (AMH) and an ultrasound count of antral follicles (AFC). Both correlate with how many eggs you are likely to produce during stimulation. In women over 40 starting their first IVF cycle, AFC was found to be the best predictor of live birth, even outperforming age slightly in predictive accuracy.²³

The relationship is not perfectly straightforward, though. A study that looked at cumulative live birth across an entire first cycle (including all frozen transfers from the same retrieval) found that while higher AMH and AFC were associated with better outcomes in simple analysis, once you accounted for the woman’s age and how many embryos were available, neither marker independently predicted cumulative live birth.²⁴ In practical terms, AMH and AFC are useful for planning your stimulation protocol and predicting how your ovaries will respond, but they do not seal your fate. A low AMH does not mean IVF cannot work on the first try; it means the clinic may need to adjust its approach and manage expectations about egg numbers.

These markers also help predict risk on the other end of the spectrum. Very high AMH and AFC values flag a higher chance of ovarian hyperstimulation syndrome, a painful and occasionally dangerous overresponse to fertility medications. One study found that AMH had the strongest predictive accuracy for this complication.²⁵ In those high-responder cases, a freeze-all strategy (retrieving eggs, freezing all resulting embryos, and transferring later) can protect the patient from hyperstimulation while preserving good-quality embryos for transfer in a subsequent, safer cycle.

Does Stress Affect First-Cycle Outcomes

This is one of the most common questions couples going through IVF ask, and the answer is more reassuring than many expect. A study that measured depression and anxiety before IVF treatment began found that neither was a significant predictor of first-cycle outcome after accounting for factors like age, duration of infertility, and ethnicity.²⁶ The persistent myth that you need to “just relax” to get pregnant is not supported by the IVF data. That said, psychological distress does influence whether people continue treatment after a failed cycle, which indirectly affects their cumulative chances. Managing stress is important for the person going through IVF, but for their own well-being rather than because it changes the biology of the first cycle.

The Add-On Industry

Fertility clinics increasingly offer a menu of optional extras that promise to improve your chances. These range from time-lapse embryo imaging to assisted hatching to endometrial scratching to specialized culture media. The evidence behind most of these add-ons is thin. A review of commonly offered IVF add-ons found limited supporting evidence for nearly all of them.²⁷ A large systematic review and meta-review of randomized trials reached the same conclusion: most add-ons are not proven to benefit patients, and the quality of evidence behind them is generally poor.²⁸

Patients are often offered these extras at a time when they are emotionally vulnerable and willing to try anything. A separate critique noted that patients are routinely charged for add-ons they are told may improve their chances despite no clinical evidence supporting the claim.²⁹ This does not mean every add-on is useless, but it does mean you should ask your clinic specifically what evidence supports each extra they recommend, and whether that evidence comes from well-designed randomized trials or from preliminary studies and marketing materials.

One add-on that has more nuanced evidence is the endometrial receptivity array (ERA), a test that attempts to identify each patient’s personal window of implantation. The concept has biological plausibility: the window when the uterine lining is receptive to an embryo lasts only a few days and varies between women.³⁰ Some research suggests ERA-guided transfers may help patients with recurrent implantation failure.³¹ But for a first-time IVF patient without a history of failed implantation, there is no strong case for adding it.

Clinic Variation Is Real

Not all clinics produce the same results, and the gap between high-performing and low-performing labs is wider than many patients realize. A multicenter analysis of over 240,000 cycles found that standardizing laboratory and clinical procedures was essential for reducing variability between centers.³² Lab conditions like incubator stability, air quality, and embryologist skill all affect embryo survival and development in ways that are invisible to the patient but show up clearly in success rate data. When comparing clinics, look for age-adjusted live-birth rates rather than raw pregnancy rates, and be wary of clinics that cherry-pick favorable patient populations to inflate their published numbers.

In many countries, national registries publish clinic-level success rates. These can be useful for spotting outliers, but they require careful interpretation. A clinic that takes on more difficult cases (older patients, patients with multiple failed cycles elsewhere) will naturally report lower success rates than one that selects only favorable cases. The most informative comparison is between your prognosis at one clinic versus another, not between the clinics’ headline figures.